High incidence of fistula formation during bevacizumab treatment in rectal cancer patients [3]

Acta Oncologica

Volumn 46, Issue 4, 2007, Pages 550-553

  Wolf, Ido ^a,b   Urban, Damien ^a   Pfeffer, Raphael ^a,b   Catane, Raphael ^a,b   Aderka, Dan ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; COLORECTAL CANCER; DEMOGRAPHY; DRUG WITHDRAWAL; FEMALE; HUMAN; LETTER; MALE; MEDICAL RECORD; PRIORITY JOURNAL; RECTOCUTANEOUS FISTULA; RECTOVAGINAL FISTULA; RECTUM CANCER; RECTUM FISTULA; RECTUM PERFORATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MALE; MIDDLE AGED; RECTAL FISTULA; RECTAL NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34248590881     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860601009471     Document Type: Letter

References (10)

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
2. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-12.
3. Giantonio BJ, Catalano NJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer. Results from the Eastern Cooperative Oncology Group (ECOG) study E3200, Abstract. J Clin Oncol 2005;23:S2.
4. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005;69(Suppl 3):25-33.
5. Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf 2006;5:553-66.
6. Lordick F, Geinitz H, Theisen J, Sendler A, Sarbia M. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: Report of three cases. Int J Radiat Oncol Biol Phys 2006;64:1295-8.
7. Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005;23:8136-9.
8. Colon and rectum. In: American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002. p 113-24.
9. Cannistra SA, Matulonis U, Penson R, Wenham R, Armstrong D, Burger RA, et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J Clin Oncol 2006;24:5006.
10. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91.